{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:01:30Z","timestamp":1793084490959,"version":"4.5.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>Cardiovascular disease still remains the leading cause of morbidity and mortality worldwide. Current pharmacological or interventional treatments help to tackle symptoms and even reduce mortality, but cardiovascular disease cases continue to rise. The emergence of novel therapeutic strategies that precisely and efficiently combat cardiovascular disease is therefore deemed more essential than ever. RNA editing, the cell-intrinsic deamination of adenosine or cytidine RNA residues, changes the molecular identity of edited nucleotides, severely altering the fate of RNA molecules involved in key biological processes. The most common type of RNA editing is the deamination of adenosine residue to inosine (A-to-I), which is catalysed by adenosine deaminases acting on RNA (ADARs). Recent efforts have convincingly liaised RNA editing-based mechanisms to the pathophysiology of the cardiovascular system. In this review, we will briefly introduce the basic concepts of the RNA editing field of research. We will particularly focus our discussion on the therapeutic exploitation of RNA editing as a novel therapeutic tool as well as the future perspectives for its use in cardiovascular disease treatment.<\/jats:p>","DOI":"10.1007\/s10557-022-07391-3","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T07:03:38Z","timestamp":1665731018000},"page":"401-411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["RNA Editing Therapeutics: Advances, Challenges and Perspectives on Combating Heart Disease"],"prefix":"10.1007","volume":"37","author":[{"given":"Maria","family":"Birgaoanu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sachse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4144-4305","authenticated-orcid":false,"given":"Aikaterini","family":"Gatsiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"issue":"3","key":"7391_CR1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1242\/dev.00953","volume":"131","author":"BV Latinkic","year":"2004","unstructured":"Latinkic BV, et al. Transcriptional regulation of the cardiac-specific MLC2 gene during Xenopus embryonic development. Development. 2004;131(3):669\u201379.","journal-title":"Development"},{"issue":"12","key":"7391_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nrg3813","volume":"15","author":"S Gerstberger","year":"2014","unstructured":"Gerstberger S, Hafner M, Tuschl T. A census of human RNA-binding proteins. Nat Rev Genet. 2014;15(12):829\u201345.","journal-title":"Nat Rev Genet"},{"issue":"8","key":"7391_CR3","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1073\/pnas.86.8.2647","volume":"86","author":"RW Wagner","year":"1989","unstructured":"Wagner RW, et al. A double-stranded RNA unwinding activity introduces structural alterations by means of adenosine to inosine conversions in mammalian cells and Xenopus eggs. Proc Natl Acad Sci USA. 1989;86(8):2647\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"7391_CR4","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1089\/ars.2017.7295","volume":"29","author":"A Gatsiou","year":"2018","unstructured":"Gatsiou A, et al. Adenosine-to-inosine RNA editing in health and disease. Antioxid Redox Signal. 2018;29(9):846\u201363.","journal-title":"Antioxid Redox Signal"},{"issue":"11","key":"7391_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/gm508","volume":"5","author":"W Slotkin","year":"2013","unstructured":"Slotkin W, Nishikura K. Adenosine-to-inosine RNA editing and human disease. Genome Med. 2013;5(11):105.","journal-title":"Genome Med"},{"issue":"20","key":"7391_CR6","doi-asserted-by":"publisher","first-page":"10801","DOI":"10.1093\/nar\/gkz815","volume":"47","author":"Y Wang","year":"2019","unstructured":"Wang Y, et al. RNA binding candidates for human ADAR3 from substrates of a gain of function mutant expressed in neuronal cells. Nucleic Acids Res. 2019;47(20):10801\u201314.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"7391_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrm.2015.4","volume":"17","author":"K Nishikura","year":"2016","unstructured":"Nishikura K. A-to-I editing of coding and non-coding RNAs by ADARs. Nat Rev Mol Cell Biol. 2016;17(2):83\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"7391_CR8","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1101\/gr.203992.116","volume":"26","author":"MG Blango","year":"2016","unstructured":"Blango MG, Bass BL. Identification of the long, edited dsRNAome of LPS-stimulated immune cells. Genome Res. 2016;26(6):852\u201362.","journal-title":"Genome Res"},{"key":"7391_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/ncomms1324","volume":"2","author":"JM Eggington","year":"2011","unstructured":"Eggington JM, Greene T, Bass BL. Predicting sites of ADAR editing in double-stranded RNA. Nat Commun. 2011;2:319.","journal-title":"Nat Commun"},{"issue":"9","key":"7391_CR10","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1101\/gr.2855504","volume":"14","author":"DD Kim","year":"2004","unstructured":"Kim DD, et al. Widespread RNA editing of embedded alu elements in the human transcriptome. Genome Res. 2004;14(9):1719\u201325.","journal-title":"Genome Res"},{"issue":"11","key":"7391_CR11","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41592-019-0610-9","volume":"16","author":"SH Roth","year":"2019","unstructured":"Roth SH, Levanon EY, Eisenberg E. Genome-wide quantification of ADAR adenosine-to-inosine RNA editing activity. Nat Methods. 2019;16(11):1131\u20138.","journal-title":"Nat Methods"},{"issue":"6","key":"7391_CR12","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1074\/jbc.M311347200","volume":"279","author":"JC Hartner","year":"2004","unstructured":"Hartner JC, et al. Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. J Biol Chem. 2004;279(6):4894\u2013902.","journal-title":"J Biol Chem"},{"issue":"6","key":"7391_CR13","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1074\/jbc.M310162200","volume":"279","author":"Q Wang","year":"2004","unstructured":"Wang Q, et al. Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J Biol Chem. 2004;279(6):4952\u201361.","journal-title":"J Biol Chem"},{"issue":"10","key":"7391_CR14","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/nm.4172","volume":"22","author":"K Stellos","year":"2016","unstructured":"Stellos K, et al. Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation. Nat Med. 2016;22(10):1140\u201350.","journal-title":"Nat Med"},{"key":"7391_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.yjmcc.2021.07.005","volume":"160","author":"NI Vlachogiannis","year":"2021","unstructured":"Vlachogiannis NI, et al. Adenosine-to-inosine Alu RNA editing controls the stability of the pro-inflammatory long noncoding RNA NEAT1 in atherosclerotic cardiovascular disease. J Mol Cell Cardiol. 2021;160:111\u201320.","journal-title":"J Mol Cell Cardiol"},{"issue":"5","key":"7391_CR16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.neuron.2006.01.025","volume":"49","author":"PL Peng","year":"2006","unstructured":"Peng PL, et al. ADAR2-dependent RNA editing of AMPA receptor subunit GluR2 determines vulnerability of neurons in forebrain ischemia. Neuron. 2006;49(5):719\u201333.","journal-title":"Neuron"},{"issue":"6791","key":"7391_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/35017558","volume":"406","author":"M Higuchi","year":"2000","unstructured":"Higuchi M, et al. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature. 2000;406(6791):78\u201381.","journal-title":"Nature"},{"issue":"4","key":"7391_CR18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1261\/rna.072728.119","volume":"26","author":"PH Costa Cruz","year":"2020","unstructured":"Costa Cruz PH, et al. A comparative analysis of ADAR mutant mice reveals site-specific regulation of RNA editing. RNA. 2020;26(4):454\u201369.","journal-title":"RNA"},{"issue":"5","key":"7391_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrm3785","volume":"15","author":"KD Meyer","year":"2014","unstructured":"Meyer KD, Jaffrey SR. The dynamic epitranscriptome: N6-methyladenosine and gene expression control. Nat Rev Mol Cell Biol. 2014;15(5):313\u201326.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"7391_CR20","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/nbt.2398","volume":"30","author":"CX Song","year":"2012","unstructured":"Song CX, Yi C, He C. Mapping recently identified nucleotide variants in the genome and transcriptome. Nat Biotechnol. 2012;30(11):1107\u201316.","journal-title":"Nat Biotechnol"},{"key":"7391_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev-genom-090413-025405","volume":"15","author":"S Li","year":"2014","unstructured":"Li S, Mason CE. The pivotal regulatory landscape of RNA modifications. Annu Rev Genomics Hum Genet. 2014;15:127\u201350.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"9","key":"7391_CR22","doi-asserted-by":"publisher","first-page":"e001927","DOI":"10.1161\/CIRCGEN.118.001927","volume":"11","author":"A Gatsiou","year":"2018","unstructured":"Gatsiou A, Stellos K. Dawn of epitranscriptomic medicine. Circ Genom Precis Med. 2018;11(9):e001927.","journal-title":"Circ Genom Precis Med"},{"issue":"6","key":"7391_CR23","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/0092-8674(87)90510-1","volume":"50","author":"LM Powell","year":"1987","unstructured":"Powell LM, et al. A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell. 1987;50(6):831\u201340.","journal-title":"Cell"},{"issue":"9","key":"7391_CR24","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1021\/acssynbio.7b00113","volume":"6","author":"P Vogel","year":"2017","unstructured":"Vogel P, Hanswillemenke A, Stafforst T. Switching protein localization by site-directed RNA editing under control of light. ACS Synth Biol. 2017;6(9):1642\u20139.","journal-title":"ACS Synth Biol"},{"issue":"7818","key":"7391_CR25","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41586-020-2077-3","volume":"583","author":"EL Van Nostrand","year":"2020","unstructured":"Van Nostrand EL, et al. A large-scale binding and functional map of human RNA-binding proteins. Nature. 2020;583(7818):711\u20139.","journal-title":"Nature"},{"issue":"1","key":"7391_CR26","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/s41467-017-01458-8","volume":"8","author":"O Solomon","year":"2017","unstructured":"Solomon O, et al. RNA editing by ADAR1 leads to context-dependent transcriptome-wide changes in RNA secondary structure. Nat Commun. 2017;8(1):1440.","journal-title":"Nat Commun"},{"issue":"7","key":"7391_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.tibs.2010.02.008","volume":"35","author":"HA Hundley","year":"2010","unstructured":"Hundley HA, Bass BL. ADAR editing in double-stranded UTRs and other noncoding RNA sequences. Trends Biochem Sci. 2010;35(7):377\u201383.","journal-title":"Trends Biochem Sci"},{"issue":"5","key":"7391_CR28","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.immuni.2015.11.001","volume":"43","author":"K Pestal","year":"2015","unstructured":"Pestal K, et al. Isoforms of RNA-editing enzyme ADAR1 independently control nucleic acid sensor MDA5-driven autoimmunity and multi-organ development. Immunity. 2015;43(5):933\u201344.","journal-title":"Immunity"},{"key":"7391_CR29","doi-asserted-by":"crossref","unstructured":"Wang Y, Liang H. When microRNAs meet RNA editing in cancer: a nucleotide change can make a difference. Bioessays.\u00a02018;40(2):1700188.","DOI":"10.1002\/bies.201700188"},{"issue":"1","key":"7391_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13059-021-02287-1","volume":"22","author":"E Park","year":"2021","unstructured":"Park E, et al. Genetic variation and microRNA targeting of A-to-I RNA editing fine tune human tissue transcriptomes. Genome Biol. 2021;22(1):77.","journal-title":"Genome Biol"},{"issue":"1","key":"7391_CR31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s12967-019-2071-4","volume":"17","author":"T Christofi","year":"2019","unstructured":"Christofi T, Zaravinos A. RNA editing in the forefront of epitranscriptomics and human health. J Transl Med. 2019;17(1):319.","journal-title":"J Transl Med"},{"issue":"2","key":"7391_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/wsbm.10","volume":"1","author":"B Zinshteyn","year":"2009","unstructured":"Zinshteyn B, Nishikura K. Adenosine-to-inosine RNA editing. Wiley Interdiscip Rev Syst Biol Med. 2009;1(2):202\u20139.","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"issue":"12","key":"7391_CR33","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/protein\/gzz005","volume":"31","author":"S Bhakta","year":"2018","unstructured":"Bhakta S, Azad MTA, Tsukahara T. Genetic code restoration by artificial RNA editing of Ochre stop codon with ADAR1 deaminase. Protein Eng Des Sel. 2018;31(12):471\u20138.","journal-title":"Protein Eng Des Sel"},{"key":"7391_CR34","doi-asserted-by":"crossref","unstructured":"\u00a0Jain M, et al. RNA editing of Filamin A pre-mRNA regulates vascular contraction and diastolic blood pressure. EMBO J.\n2018;37(19):e94813.\u00a0","DOI":"10.15252\/embj.201694813"},{"issue":"1","key":"7391_CR35","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1038\/s41467-021-21921-x","volume":"12","author":"Y Shiromoto","year":"2021","unstructured":"Shiromoto Y, et al. ADAR1 RNA editing enzyme regulates R-loop formation and genome stability at telomeres in cancer cells. Nat Commun. 2021;12(1):1654.","journal-title":"Nat Commun"},{"key":"7391_CR36","doi-asserted-by":"crossref","unstructured":"Zhao H, et al. RNase H eliminates R-loops that disrupt DNA replication but is nonessential for efficient DSB repair. EMBO Rep. 2018;19(5):e45335.","DOI":"10.15252\/embr.201745335"},{"issue":"3","key":"7391_CR37","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.cell.2019.08.055","volume":"179","author":"T Garcia-Muse","year":"2019","unstructured":"Garcia-Muse T, Aguilera A. R loops: from physiological to pathological roles. Cell. 2019;179(3):604\u201318.","journal-title":"Cell"},{"key":"7391_CR38","doi-asserted-by":"publisher","first-page":"5220","DOI":"10.1038\/ncomms6220","volume":"5","author":"R Arora","year":"2014","unstructured":"Arora R, et al. RNaseH1 regulates TERRA-telomeric DNA hybrids and telomere maintenance in ALT tumour cells. Nat Commun. 2014;5:5220.","journal-title":"Nat Commun"},{"issue":"2","key":"7391_CR39","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1261\/rna.054627.115","volume":"22","author":"K Khermesh","year":"2016","unstructured":"Khermesh K, et al. Reduced levels of protein recoding by A-to-I RNA editing in Alzheimer\u2019s disease. RNA. 2016;22(2):290\u2013302.","journal-title":"RNA"},{"issue":"8","key":"7391_CR40","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/nbt996","volume":"22","author":"EY Levanon","year":"2004","unstructured":"Levanon EY, et al. Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat Biotechnol. 2004;22(8):1001\u20135.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"7391_CR41","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1371\/journal.pbio.0020391","volume":"2","author":"A Athanasiadis","year":"2004","unstructured":"Athanasiadis A, Rich A, Maas S. Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. PLoS Biol. 2004;2(12):e391.","journal-title":"PLoS Biol"},{"issue":"5","key":"7391_CR42","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1161\/01.RES.0000060485.20318.96","volume":"92","author":"GP Shi","year":"2003","unstructured":"Shi GP, et al. Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res. 2003;92(5):493\u2013500.","journal-title":"Circ Res"},{"key":"7391_CR43","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fendo.2018.00402","volume":"9","author":"J O'Brien","year":"2018","unstructured":"O\u2019Brien J, et al. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018;9:402.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"7391_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41597-021-00979-8","volume":"8","author":"GP Marceca","year":"2021","unstructured":"Marceca GP, et al. MiREDiBase, a manually curated database of validated and putative editing events in microRNAs. Sci Data. 2021;8(1):199.","journal-title":"Sci Data"},{"issue":"D1","key":"7391_CR45","doi-asserted-by":"publisher","first-page":"D155","DOI":"10.1093\/nar\/gky1141","volume":"47","author":"A Kozomara","year":"2019","unstructured":"Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019;47(D1):D155\u201362.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"7391_CR46","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1161\/CIRCRESAHA.117.312345","volume":"122","author":"R van der Kwast","year":"2018","unstructured":"van der Kwast R, et al. Adenosine-to-inosine editing of microRNA-487b alters target gene selection after ischemia and promotes neovascularization. Circ Res. 2018;122(3):444\u201356.","journal-title":"Circ Res"},{"issue":"8","key":"7391_CR47","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1161\/CIRCRESAHA.114.304747","volume":"115","author":"SM Welten","year":"2014","unstructured":"Welten SM, et al. Inhibition of 14q32 MicroRNAs miR-329, miR-487b, miR-494, and miR-495 increases neovascularization and blood flow recovery after ischemia. Circ Res. 2014;115(8):696\u2013708.","journal-title":"Circ Res"},{"key":"7391_CR48","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.omtn.2020.07.020","volume":"21","author":"R van der Kwast","year":"2020","unstructured":"van der Kwast R, et al. Adenosine-to-inosine editing of vasoactive microRNAs alters their targetome and function in ischemia. Mol Ther Nucleic Acids. 2020;21:932\u201353.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"7391_CR49","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1161\/CIRCRESAHA.120.316932","volume":"127","author":"JBT Moore","year":"2020","unstructured":"Moore JBT, et al. The A-to-I RNA editing enzyme adar1 is essential for normal embryonic cardiac growth and development. Circ Res. 2020;127(4):550\u20132.","journal-title":"Circ Res"},{"key":"7391_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fcvm.2020.00030","volume":"7","author":"H El Azzouzi","year":"2020","unstructured":"El Azzouzi H, et al. Cardiomyocyte specific deletion of ADAR1 causes severe cardiac dysfunction and increased lethality. Front Cardiovasc Med. 2020;7:30.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"7391_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nsmb1041","volume":"13","author":"W Yang","year":"2006","unstructured":"Yang W, et al. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat Struct Mol Biol. 2006;13(1):13\u201321.","journal-title":"Nat Struct Mol Biol"},{"issue":"11","key":"7391_CR52","doi-asserted-by":"publisher","first-page":"22796","DOI":"10.3390\/ijms141122796","volume":"14","author":"S Tomaselli","year":"2013","unstructured":"Tomaselli S, et al. ADAR enzyme and miRNA story: a nucleotide that can make the difference. Int J Mol Sci. 2013;14(11):22796\u2013816.","journal-title":"Int J Mol Sci"},{"key":"7391_CR53","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1038\/ncomms3271","volume":"4","author":"ES Vik","year":"2013","unstructured":"Vik ES, et al. Endonuclease V cleaves at inosines in RNA. Nat Commun. 2013;4:2271.","journal-title":"Nat Commun"},{"issue":"4","key":"7391_CR54","doi-asserted-by":"publisher","first-page":"e0200968","DOI":"10.1371\/journal.pone.0200968","volume":"14","author":"F Altaf","year":"2019","unstructured":"Altaf F, et al. Modulation of ADAR mRNA expression in patients with congenital heart defects. PLoS ONE. 2019;14(4):e0200968.","journal-title":"PLoS ONE"},{"issue":"1","key":"7391_CR55","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/s41467-017-01737-4","volume":"8","author":"Y Sassi","year":"2017","unstructured":"Sassi Y, et al. Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling. Nat Commun. 2017;8(1):1614.","journal-title":"Nat Commun"},{"issue":"1","key":"7391_CR56","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ymthe.2021.07.004","volume":"30","author":"X Wu","year":"2022","unstructured":"Wu X, et al. ADAR2 increases in exercised heart and protects against myocardial infarction and doxorubicin-induced cardiotoxicity. Mol Ther. 2022;30(1):400\u201314.","journal-title":"Mol Ther"},{"key":"7391_CR57","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.omtn.2017.07.014","volume":"8","author":"CPC Gomes","year":"2017","unstructured":"Gomes CPC, et al. The function and therapeutic potential of long non-coding RNAs in cardiovascular development and disease. Mol Ther Nucleic Acids. 2017;8:494\u2013507.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"7391_CR58","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41467-020-14621-5","volume":"11","author":"SJ Tang","year":"2020","unstructured":"Tang SJ, et al. Cis- and trans-regulations of pre-mRNA splicing by RNA editing enzymes influence cancer development. Nat Commun. 2020;11(1):799.","journal-title":"Nat Commun"},{"issue":"6","key":"7391_CR59","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1101\/gr.231209.117","volume":"28","author":"YE Hsiao","year":"2018","unstructured":"Hsiao YE, et al. RNA editing in nascent RNA affects pre-mRNA splicing. Genome Res. 2018;28(6):812\u201323.","journal-title":"Genome Res"},{"issue":"5","key":"7391_CR60","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nbt.2890","volume":"32","author":"WR Jeck","year":"2014","unstructured":"Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol. 2014;32(5):453\u201361.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"7391_CR61","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41419-021-03743-3","volume":"12","author":"L Verduci","year":"2021","unstructured":"Verduci L, et al. CircRNAs: role in human diseases and potential use as biomarkers. Cell Death Dis. 2021;12(5):468.","journal-title":"Cell Death Dis"},{"key":"7391_CR62","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.yjmcc.2018.08.012","volume":"122","author":"MY Zhou","year":"2018","unstructured":"Zhou MY, Yang JM, Xiong XD. The emerging landscape of circular RNA in cardiovascular diseases. J Mol Cell Cardiol. 2018;122:134\u20139.","journal-title":"J Mol Cell Cardiol"},{"key":"7391_CR63","doi-asserted-by":"crossref","unstructured":"Kokot K E, Kneuer J M, John D. et al. Reduction of A-to-I RNA editing in the failing human heart regulates formation of circular RNAs. Basic Res Cardiol. 2018;117(1):32.","DOI":"10.1007\/s00395-022-00940-9"},{"issue":"3","key":"7391_CR64","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1161\/CIRCRESAHA.116.309003","volume":"119","author":"J Fei","year":"2016","unstructured":"Fei J, et al. ADAR1-mediated RNA editing, a novel mechanism controlling phenotypic modulation of vascular smooth muscle cells. Circ Res. 2016;119(3):463\u20139.","journal-title":"Circ Res"},{"key":"7391_CR65","doi-asserted-by":"crossref","unstructured":"Musunuru K. Moving toward genome-editing therapies for cardiovascular diseases. J Clin Invest. 2022;132(1):e148555.","DOI":"10.1172\/JCI148555"},{"issue":"1","key":"7391_CR66","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41467-018-04252-2","volume":"9","author":"M Adli","year":"2018","unstructured":"Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun. 2018;9(1):1911.","journal-title":"Nat Commun"},{"issue":"6","key":"7391_CR67","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262\u201378.","journal-title":"Cell"},{"issue":"8","key":"7391_CR68","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1053\/j.semperi.2018.09.008","volume":"42","author":"A Hong","year":"2018","unstructured":"Hong A. CRISPR in personalized medicine: industry perspectives in gene editing. Semin Perinatol. 2018;42(8):501\u20137.","journal-title":"Semin Perinatol"},{"issue":"4","key":"7391_CR69","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1261\/rna.030882.111","volume":"18","author":"SH Sternberg","year":"2012","unstructured":"Sternberg SH, Haurwitz RE, Doudna JA. Mechanism of substrate selection by a highly specific CRISPR endoribonuclease. RNA. 2012;18(4):661\u201372.","journal-title":"RNA"},{"issue":"44","key":"7391_CR70","doi-asserted-by":"publisher","first-page":"11166","DOI":"10.1002\/anie.201206489","volume":"51","author":"T Stafforst","year":"2012","unstructured":"Stafforst T, Schneider MF. An RNA-deaminase conjugate selectively repairs point mutations. Angew Chem Int Ed Engl. 2012;51(44):11166\u20139.","journal-title":"Angew Chem Int Ed Engl"},{"key":"7391_CR71","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/978-1-0716-0787-9_19","volume":"2181","author":"T Merkle","year":"2021","unstructured":"Merkle T, Stafforst T. New frontiers for site-directed RNA editing: harnessing endogenous ADARs. Methods Mol Biol. 2021;2181:331\u201349.","journal-title":"Methods Mol Biol"},{"issue":"6366","key":"7391_CR72","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1126\/science.aaq0180","volume":"358","author":"DBT Cox","year":"2017","unstructured":"Cox DBT, et al. RNA editing with CRISPR-Cas13. Science. 2017;358(6366):1019\u201327.","journal-title":"Science"},{"issue":"8","key":"7391_CR73","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.tibtech.2018.03.004","volume":"36","author":"F Nami","year":"2018","unstructured":"Nami F, et al. Strategies for in vivo genome editing in nondividing cells. Trends Biotechnol. 2018;36(8):770\u201386.","journal-title":"Trends Biotechnol"},{"key":"7391_CR74","doi-asserted-by":"publisher","first-page":"677587","DOI":"10.3389\/fcell.2021.677587","volume":"9","author":"T Tang","year":"2021","unstructured":"Tang T, et al. Programmable system of Cas13-mediated RNA modification and its biological and biomedical applications. Front Cell Dev Biol. 2021;9:677587.","journal-title":"Front Cell Dev Biol"},{"issue":"27","key":"7391_CR75","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"issue":"7830","key":"7391_CR76","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett KS, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567\u201371.","journal-title":"Nature"},{"issue":"12","key":"7391_CR77","doi-asserted-by":"publisher","first-page":"e0006108","DOI":"10.1371\/journal.pntd.0006108","volume":"11","author":"L Stitz","year":"2017","unstructured":"Stitz L, et al. A thermostable messenger RNA based vaccine against rabies. PLoS Negl Trop Dis. 2017;11(12):e0006108.","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"7391_CR78","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","volume":"25","author":"K Bahl","year":"2017","unstructured":"Bahl K, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther. 2017;25(6):1316\u201327.","journal-title":"Mol Ther"},{"issue":"12","key":"7391_CR79","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","volume":"36","author":"S John","year":"2018","unstructured":"John S, et al. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine. 2018;36(12):1689\u201399.","journal-title":"Vaccine"},{"issue":"6","key":"7391_CR80","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","volume":"168","author":"JM Richner","year":"2017","unstructured":"Richner JM, et al. Modified mRNA vaccines protect against Zika virus infection. Cell. 2017;168(6):1114-1125 e10.","journal-title":"Cell"},{"issue":"4","key":"7391_CR81","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","volume":"46","author":"X Shen","year":"2018","unstructured":"Shen X, Corey DR. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. 2018;46(4):1584\u2013600.","journal-title":"Nucleic Acids Res"},{"issue":"7228","key":"7391_CR82","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature07754","volume":"457","author":"H Siomi","year":"2009","unstructured":"Siomi H, Siomi MC. On the road to reading the RNA-interference code. Nature. 2009;457(7228):396\u2013404.","journal-title":"Nature"},{"key":"7391_CR83","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1038\/mtna.2015.23","volume":"4","author":"JK Lam","year":"2015","unstructured":"Lam JK, et al. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015;4:e252.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"7391_CR84","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrd.2016.199","volume":"16","author":"J Zhou","year":"2017","unstructured":"Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2017;16(3):181\u2013202.","journal-title":"Nat Rev Drug Discov"},{"key":"7391_CR85","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3389\/fphys.2018.00953","volume":"9","author":"A Laina","year":"2018","unstructured":"Laina A, et al. RNA therapeutics in cardiovascular precision medicine. Front Physiol. 2018;9:953.","journal-title":"Front Physiol"},{"issue":"5","key":"7391_CR86","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","volume":"25","author":"CA Stein","year":"2017","unstructured":"Stein CA, Castanotto D. FDA-approved oligonucleotide therapies in 2017. Mol Ther. 2017;25(5):1069\u201375.","journal-title":"Mol Ther"},{"issue":"2","key":"7391_CR87","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2125.2012.04469.x","volume":"76","author":"ST Crooke","year":"2013","unstructured":"Crooke ST, Geary RS. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol. 2013;76(2):269\u201376.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"7391_CR88","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jacl.2016.02.018","volume":"10","author":"FJ Raal","year":"2016","unstructured":"Raal FJ, et al. Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. J Clin Lipidol. 2016;10(4):860\u20139.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"7391_CR89","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pcad.2015.04.004","volume":"58","author":"L Joseph","year":"2015","unstructured":"Joseph L, Robinson JG. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibition and the future of lipid lowering therapy. Prog Cardiovasc Dis. 2015;58(1):19\u201331.","journal-title":"Prog Cardiovasc Dis"},{"issue":"9911","key":"7391_CR90","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","volume":"383","author":"K Fitzgerald","year":"2014","unstructured":"Fitzgerald K, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014;383(9911):60\u20138.","journal-title":"Lancet"},{"key":"7391_CR91","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3389\/fgene.2018.00507","volume":"9","author":"F Robert","year":"2018","unstructured":"Robert F, Pelletier J. Exploring the impact of single-nucleotide polymorphisms on translation. Front Genet. 2018;9:507.","journal-title":"Front Genet"},{"issue":"12","key":"7391_CR92","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/gt.2017.90","volume":"24","author":"MTA Azad","year":"2017","unstructured":"Azad MTA, Bhakta S, Tsukahara T. Site-directed RNA editing by adenosine deaminase acting on RNA for correction of the genetic code in gene therapy. Gene Ther. 2017;24(12):779\u201386.","journal-title":"Gene Ther"},{"issue":"11","key":"7391_CR93","doi-asserted-by":"publisher","first-page":"5366","DOI":"10.1093\/nar\/gky397","volume":"46","author":"PH Hagedorn","year":"2018","unstructured":"Hagedorn PH, et al. Identifying and avoiding off-target effects of RNase H-dependent antisense oligonucleotides in mice. Nucleic Acids Res. 2018;46(11):5366\u201380.","journal-title":"Nucleic Acids Res"},{"issue":"22","key":"7391_CR94","doi-asserted-by":"publisher","first-page":"e104741","DOI":"10.15252\/embj.2020104741","volume":"39","author":"X Huang","year":"2020","unstructured":"Huang X, et al. Programmable C-to-U RNA editing using the human APOBEC3A deaminase. EMBO J. 2020;39(22):e104741.","journal-title":"EMBO J"},{"key":"7391_CR95","doi-asserted-by":"crossref","unstructured":"Han W, et al. Programmable RNA base editing with a single gRNA-free enzyme. Nucleic Acids Res. 2022;50(16):9580\u201395.","DOI":"10.1093\/nar\/gkac713"},{"issue":"1","key":"7391_CR96","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.cell.2019.05.049","volume":"178","author":"S Rauch","year":"2019","unstructured":"Rauch S, et al. Programmable RNA-guided RNA effector proteins built from human parts. Cell. 2019;178(1):122-134 e12.","journal-title":"Cell"},{"key":"7391_CR97","doi-asserted-by":"crossref","unstructured":"Pecori R, et al. Functions and consequences of AID\/APOBEC-mediated DNA and RNA deamination. Nat Rev Genet. 2022;23(8):505\u201315.","DOI":"10.1038\/s41576-022-00459-8"},{"key":"7391_CR98","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-biochem-060208-105251","volume":"79","author":"K Nishikura","year":"2010","unstructured":"Nishikura K. Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem. 2010;79:321\u201349.","journal-title":"Annu Rev Biochem"},{"issue":"5203","key":"7391_CR99","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1126\/science.7878468","volume":"267","author":"SM Rueter","year":"1995","unstructured":"Rueter SM, et al. Glutamate receptor RNA editing in vitro by enzymatic conversion of adenosine to inosine. Science. 1995;267(5203):1491\u20134.","journal-title":"Science"},{"issue":"4","key":"7391_CR100","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4161\/rna.6925","volume":"5","author":"S Kwak","year":"2008","unstructured":"Kwak S, Nishimoto Y, Yamashita T. Newly identified ADAR-mediated A-to-I editing positions as a tool for ALS research. RNA Biol. 2008;5(4):193\u20137.","journal-title":"RNA Biol"},{"key":"7391_CR101","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.omtn.2019.12.042","volume":"19","author":"G Aquino-Jarquin","year":"2020","unstructured":"Aquino-Jarquin G. Novel engineered programmable systems for ADAR-mediated RNA editing. Mol Ther Nucleic Acids. 2020;19:1065\u201372.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"7391_CR102","first-page":"2797","volume":"45","author":"J Wettengel","year":"2017","unstructured":"Wettengel J, et al. Harnessing human ADAR2 for RNA repair \u2013 recoding a PINK1 mutation rescues mitophagy. Nucleic Acids Res. 2017;45(5):2797\u2013808.","journal-title":"Nucleic Acids Res"},{"key":"7391_CR103","doi-asserted-by":"publisher","first-page":"41478","DOI":"10.1038\/srep41478","volume":"7","author":"M Fukuda","year":"2017","unstructured":"Fukuda M, et al. Construction of a guide-RNA for site-directed RNA mutagenesis utilising intracellular A-to-I RNA editing. Sci Rep. 2017;7:41478.","journal-title":"Sci Rep"},{"key":"7391_CR104","doi-asserted-by":"crossref","unstructured":"Reautschnig P, et al. CLUSTER guide RNAs enable precise and efficient RNA editing with endogenous ADAR enzymes in vivo. Nat Biotechnol. 2022;40(5):759\u201368.","DOI":"10.1038\/s41587-021-01105-0"},{"issue":"2","key":"7391_CR105","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41587-019-0013-6","volume":"37","author":"T Merkle","year":"2019","unstructured":"Merkle T, et al. Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides. Nat Biotechnol. 2019;37(2):133\u20138.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"7391_CR106","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41587-019-0090-6","volume":"37","author":"JL Litke","year":"2019","unstructured":"Litke JL, Jaffrey SR. Highly efficient expression of circular RNA aptamers in cells using autocatalytic transcripts. Nat Biotechnol. 2019;37(6):667\u201375.","journal-title":"Nat Biotechnol"},{"key":"7391_CR107","doi-asserted-by":"crossref","unstructured":"Katrekar D, et al. Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs. Nat Biotechnol. 2022;40(6):938\u201345.","DOI":"10.1038\/s41587-021-01171-4"},{"issue":"sup1","key":"7391_CR108","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/15476286.2021.1983288","volume":"18","author":"HM Khosravi","year":"2021","unstructured":"Khosravi HM, Jantsch MF. Site-directed RNA editing: recent advances and open challenges. RNA Biol. 2021;18(sup1):41\u201350.","journal-title":"RNA Biol"},{"issue":"3","key":"7391_CR109","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.molcel.2015.10.008","volume":"60","author":"S Shmakov","year":"2015","unstructured":"Shmakov S, et al. Discovery and functional characterization of diverse class 2 CRISPR-Cas systems. Mol Cell. 2015;60(3):385\u201397.","journal-title":"Mol Cell"},{"issue":"5","key":"7391_CR110","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41592-021-01124-4","volume":"18","author":"C Xu","year":"2021","unstructured":"Xu C, et al. Programmable RNA editing with compact CRISPR-Cas13 systems from uncultivated microbes. Nat Methods. 2021;18(5):499\u2013506.","journal-title":"Nat Methods"},{"issue":"22","key":"7391_CR111","doi-asserted-by":"publisher","first-page":"e104748","DOI":"10.15252\/embj.2020104748","volume":"39","author":"Y Liu","year":"2020","unstructured":"Liu Y, et al. REPAIRx, a specific yet highly efficient programmable A > I RNA base editor. EMBO J. 2020;39(22):e104748.","journal-title":"EMBO J"},{"issue":"6451","key":"7391_CR112","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1126\/science.aax7063","volume":"365","author":"OO Abudayyeh","year":"2019","unstructured":"Abudayyeh OO, et al. A cytosine deaminase for programmable single-base RNA editing. Science. 2019;365(6451):382\u20136.","journal-title":"Science"},{"issue":"6","key":"7391_CR113","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.devcel.2020.07.013","volume":"54","author":"G Kushawah","year":"2020","unstructured":"Kushawah G, et al. CRISPR-Cas13d induces efficient mRNA knockdown in animal embryos. Dev Cell. 2020;54(6):805-817 e7.","journal-title":"Dev Cell"},{"issue":"3","key":"7391_CR114","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1089\/crispr.2020.0018","volume":"3","author":"AB Buchman","year":"2020","unstructured":"Buchman AB, et al. Programmable RNA targeting using CasRx in flies. CRISPR J. 2020;3(3):164\u201376.","journal-title":"CRISPR J"},{"issue":"6","key":"7391_CR115","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1093\/nar\/gkw138","volume":"44","author":"V Mekler","year":"2016","unstructured":"Mekler V, et al. Kinetics of the CRISPR-Cas9 effector complex assembly and the role of 3\u2019-terminal segment of guide RNA. Nucleic Acids Res. 2016;44(6):2837\u201345.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"7391_CR116","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/wrna.1296","volume":"6","author":"H Wei","year":"2015","unstructured":"Wei H, Wang Z. Engineering RNA-binding proteins with diverse activities. Wiley Interdiscip Rev RNA. 2015;6(6):597\u2013613.","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"7","key":"7391_CR117","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nchembio.577","volume":"7","author":"A Filipovska","year":"2011","unstructured":"Filipovska A, et al. A universal code for RNA recognition by PUF proteins. Nat Chem Biol. 2011;7(7):425\u20137.","journal-title":"Nat Chem Biol"},{"key":"7391_CR118","doi-asserted-by":"crossref","unstructured":"Monian P, et al. Endogenous ADAR-mediated RNA editing in non-human primates using stereopure chemically modified oligonucleotides. Nat Biotechnol. 2022;40(7):1093\u2013102.","DOI":"10.1038\/s41587-022-01225-1"},{"issue":"7859","key":"7391_CR119","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru K, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593(7859):429\u201334.","journal-title":"Nature"},{"issue":"2","key":"7391_CR120","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154\u20136.","journal-title":"Nat Genet"},{"issue":"7","key":"7391_CR121","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41587-020-0491-6","volume":"38","author":"NM Gaudelli","year":"2020","unstructured":"Gaudelli NM, et al. Directed evolution of adenine base editors with increased activity and therapeutic application. Nat Biotechnol. 2020;38(7):892\u2013900.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"7391_CR122","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1080\/15384101.2016.1176657","volume":"15","author":"J Guo","year":"2016","unstructured":"Guo J, et al. Unraveling molecular effects of ADAR1 overexpression in HEK293T cells by label-free quantitative proteomics. Cell Cycle. 2016;15(12):1591\u2013601.","journal-title":"Cell Cycle"},{"issue":"12","key":"7391_CR123","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1016\/j.ajpath.2015.08.002","volume":"185","author":"G Wang","year":"2015","unstructured":"Wang G, et al. ADAR1 Prevents liver injury from inflammation and suppresses interferon production in hepatocytes. Am J Pathol. 2015;185(12):3224\u201337.","journal-title":"Am J Pathol"},{"issue":"12","key":"7391_CR124","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/d41573-019-00179-5","volume":"18","author":"M Cully","year":"2019","unstructured":"Cully M. Chemical inhibitors make their RNA epigenetic mark. Nat Rev Drug Discov. 2019;18(12):892\u20134.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07391-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-022-07391-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07391-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T16:08:05Z","timestamp":1678810085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-022-07391-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":124,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["7391"],"URL":"https:\/\/doi.org\/10.1007\/s10557-022-07391-3","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"assertion":[{"value":"1 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with animals performed by any of the authors. This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}